LevitasBio Launches LeviSelect Suite of Cell Depletion & Enrichment Kits
7.2.2023 15:53:00 EET | Business Wire | Press release
LevitasBio, Inc. (www.levitasbio.com), a premier end-to-end sample processing and cellular analysis provider to the life sciences market, unveils a suite of LeviSelect™ cell depletion and enrichment kits for immunology research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005645/en/
Five new LeviSelect Immune Cell Kits enable targeted enrichment of CD3 T Cells, CD4 T Cells, CD8 T Cells and Pan B Cells. Additional kits are also available under early access. (Graphic: Business Wire)
LeviSelect Kits are a targeted expansion of the revolutionary LeviCell™ Advanced Workflow fully integrated protocol that delivers an important new approach to cellular isolation and analysis, offering:
- Cells of interest are entirely label-free, unmodified or unperturbed with no gene expression or activation changes
- Live-cell enrichment, debris removal, and targeted selection all occur in a single simple step with no additional purifications, filtrations or consumables required
- Multiple LeviSelect kits can be multiplexed for a powerful and extremely targeted approach
For oncology or immuno-oncology research, LeviSelect CD45 Depletion Kits provide a highly effective method for the enrichment of pure tumor cells enabling characterization for drug discovery and biomarker identification.
LeviSelect Immune Kits support target selection of the immune subpopulations required for downstream cell analysis or further subsetting. Researchers can enrich hematopoietic populations quickly without lengthy workflows or potential cell activation.
- CD3 Enrichment
- CD4 Enrichment
- CD8 Enrichment
- Pan B Enrichment
- Pan Monocyte Enrichment
- NK Cell Enrichment
- Neutrophil Enrichment
Now T Cells, B Cells, NK Cell and Monocytes can be enriched simultaneously with viable cell enrichment in an untouched and unbiased manner. Future LeviSelect kits will include subtypes from these major populations.
“With the immediate launch of seven LeviSelect Kits—and six more available via our Early Access program—LevitasBio is enabling the streamline enrichment of these cells for downstream cell-based assays or immune profiling studies,” stated Martin Pieprzyk, CEO of LevitasBio. “This is highly impactful to catalyze novel discoveries in both academic and biopharma discovery research.”
Researchers, scientists, and labs who would like exclusive, priority access to future LeviSelect Kits can join the LevitasBio Early Access Program at https://levitasbio.com/early-access-program.
LevitasBio —True Biology Begins Here
Our mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005645/en/
Contact information
Steven Collier
Communication Liaison
steve@levitasbio.com
650-229-8596
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Launches Behavioral Science Center of Excellence to Decode and Predict Health Care Decisions in a Rapidly Evolving Biopharma Landscape30.9.2026 16:00:00 EEST | Press release
Blue Matter today announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the Blue Matter Insights primary market research team. The CoE applies behavioral science as a strategic lens to decode the “why” behind the decisions made by healthcare professionals, patients, care partners, and other stakeholders. Biopharma decisions hinge on knowing why customers do what they do. Traditional research does a good job of capturing what stakeholders say but often misses the unconscious drivers, biases, emotions, and contexts that shape behavior. The result is an incomplete picture in the moments where clarity matters most, including when developing positioning strategies, planning product launches, and making major lifecycle decisions. "You don't need a survey to tell you that physicians see efficacy as the most important treatment decision driver," said Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter. "What our clien
934 Embeds Bluefin Payment Security into Juno to Advance Secure, Connected Hospitality Payments30.9.2026 16:00:00 EEST | Press release
Bluefin, a global leader in payment and data security, and 934, a global provider of connected payment technology for the hospitality industry, today announced a partnership to integrate Bluefin’s payment security capabilities into Juno, 934’s hospitality payment platform. Hospitality businesses increasingly operate across connected payment environments spanning hotels, restaurants, resorts and other guest experiences. Behind those interactions are multiple systems, workflows and payment technologies that must work together while protecting sensitive payment data. Juno is designed to connect those experiences through a unified hospitality payment environment. By incorporating Bluefin’s security technology into the platform architecture, 934 can provide customers globally with access to PCI-validated point-to-point encryption (P2PE) for card-present payments and tokenization for protecting sensitive payment data. The result is a security-first approach in which payment protection is bui
Blackfuel Emerges From Stealth with More Than $250 Million in Contracted Revenue to Build a Global AI Token Grid30.9.2026 16:00:00 EEST | Press release
Blackfuel today emerged from stealth with more than $250 million in contracted revenue under multi-year customer agreements, unveiling its ambition to build a global AI Token Grid. Pioneering the AI Token Grid, Blackfuel is building a network of architecture-specific accelerator clusters connected through a common software and commercial layer, designed to turn dedicated compute into measurable, reservable AI output. By collaborating with AMD and NTT DATA, Blackfuel is developing its European-operated inference capacity, beginning with a GPU cluster currently being delivered in Europe. "The cloud was built around virtual machines. The next infrastructure layer will be built around tokens. We are building Blackfuel to become one of the world's defining AI compute companies, starting with our first deployments in Europe. That means bringing industrial-scale infrastructure, software and capital together so customers can buy intelligence with the same predictability with which they buy pow
Visioneering Technologies' New Contact Lens Trial Shows Landmark Results in Slowing Children's Nearsightedness30.9.2026 15:59:00 EEST | Press release
Visioneering Technologies, Inc. (VTI), a medical device company that designs and markets specialty contact lenses, will announce completed three-year results from PROTECT, a prospective, double-masked, multinational randomized controlled trial evaluating the company's NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens for slowing the progression of myopia, or nearsightedness, in children. Ashley Tuan, OD, MS, PhD, VTI's Chief Medical Officer, will present the full findings at the American Academy of Optometry's annual meeting in Anaheim. Myopia develops when a child's eye grows too long, causing distant objects to appear blurry, and it typically worsens through childhood. Faster progression is associated with a higher lifelong risk of more serious eye conditions, including retinal detachment and myopic maculopathy, a leading cause of permanent vision loss. Slowing that progression, even modestly, is considered clinically meaningful.3,4 Over three years, children who wore NaturalVu
Lyft App Launches in Europe30.9.2026 15:00:00 EEST | Press release
Starting today, Lyft (NASDAQ: LYFT) riders can use their Lyft app in cities across Europe. Early access to the Lyft app rolls out in Barcelona and Hamburg first; throughout October, the Lyft app will become available for riders to use in some of Europe’s largest cities including London, Rome, Paris, Berlin, Athens, and Warsaw. By the end of October riders visiting Spain, Italy, Greece, Poland, England, Scotland, Ireland, Austria, France, and Germany will have one go-to app when they cross the Atlantic, building on the foundations from this past summer beta testing the Lyft app in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930010726/en/ The Lyft app is now available in Europe “Millions of riders across North America trust Lyft to get them where they’re going every day. Now that same app works the moment they land in Europe. No need to download anything new,” said Sid Patil, Lyft’s Chief Rideshare and Marketplac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom